ATE202482T1 - Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten - Google Patents

Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten

Info

Publication number
ATE202482T1
ATE202482T1 AT94910854T AT94910854T ATE202482T1 AT E202482 T1 ATE202482 T1 AT E202482T1 AT 94910854 T AT94910854 T AT 94910854T AT 94910854 T AT94910854 T AT 94910854T AT E202482 T1 ATE202482 T1 AT E202482T1
Authority
AT
Austria
Prior art keywords
permeability
protein products
antibacterial
therapeutic uses
increase protein
Prior art date
Application number
AT94910854T
Other languages
German (de)
English (en)
Inventor
Roger G Ii Little
Helene Gazzano-Santoro
James Brian Parent
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/030,644 external-priority patent/US5348942A/en
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE202482T1 publication Critical patent/ATE202482T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94910854T 1993-03-12 1994-03-11 Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten ATE202482T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/030,644 US5348942A (en) 1993-03-12 1993-03-12 Therapeutic uses of bactericidal/permeability increasing protein products
US9320293A 1993-07-15 1993-07-15
PCT/US1994/002401 WO1994020128A1 (en) 1993-03-12 1994-03-11 Therapeutic uses of bactericidal/permeability increasing protein products

Publications (1)

Publication Number Publication Date
ATE202482T1 true ATE202482T1 (de) 2001-07-15

Family

ID=26706282

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910854T ATE202482T1 (de) 1993-03-12 1994-03-11 Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten

Country Status (15)

Country Link
US (3) US5639727A (OSRAM)
EP (2) EP1129718A3 (OSRAM)
JP (3) JPH08509703A (OSRAM)
CN (2) CN1105574C (OSRAM)
AT (1) ATE202482T1 (OSRAM)
AU (1) AU684503B2 (OSRAM)
CA (1) CA2157927C (OSRAM)
DE (1) DE69427582T2 (OSRAM)
DK (1) DK0690720T3 (OSRAM)
ES (1) ES2157981T3 (OSRAM)
GR (1) GR3036686T3 (OSRAM)
MX (1) MX9401807A (OSRAM)
NZ (1) NZ263057A (OSRAM)
PT (1) PT690720E (OSRAM)
WO (1) WO1994020128A1 (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5731415A (en) 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
NZ275205A (en) * 1993-09-22 1998-03-25 Xoma Corp Use of bactericidal/permeability-increasing protein in treating gram-negative bacterial infection
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
CN1112933C (zh) * 1994-01-14 2003-07-02 爱克索马技术有限公司 抗真菌的方法和物质
DK0754050T3 (da) * 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
DE69532302D1 (de) * 1994-09-15 2004-01-22 Xoma Technology Ltd Peptide gegen pilzen
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
CA2253837C (en) 1996-05-10 2002-07-02 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
WO1997044056A1 (en) * 1996-05-23 1997-11-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999039702A2 (en) * 1997-10-31 1999-08-12 Children's Medical Center Corporation Method for regulating size and growth of vascularized normal tissue
US6264596B1 (en) 1997-11-03 2001-07-24 Meadox Medicals, Inc. In-situ radioactive medical device
US6720311B2 (en) 1997-12-18 2004-04-13 David Tsai Polypeptide for the treatment of cancer and a method for preparation thereof
US5994298A (en) * 1997-12-18 1999-11-30 Tsai; David Proteins for cancer cell specific induction of apoptosis and method for isolation thereof
US6737402B2 (en) 1997-12-18 2004-05-18 David Tsai Method of preparing fetuin to induce apoptosis
US7238662B2 (en) * 1997-12-18 2007-07-03 Ambryx Biotechnology, Inc. Alpha 2HS glycoprotein for treatment of cancer and a method for preparation thereof
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6242219B1 (en) * 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
US6515104B1 (en) * 1999-06-25 2003-02-04 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing protein
US6964948B2 (en) * 1999-06-25 2005-11-15 Xoma Technology Ltd. Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein
CA2430588A1 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd. Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
WO2004033693A1 (en) 2002-03-29 2004-04-22 Xoma Technology Ltd. Methods vectors plasmids and methods for increasing expression of recombinant polypeptides
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
US10017585B2 (en) 2010-06-17 2018-07-10 Momenta Pharmaceuticals, Inc. Methods and compositions for promoting hair growth
CN103648515B (zh) * 2011-04-05 2018-01-02 达纳-法伯癌症研究所有限公司 作为辐射缓和剂和辐射防护剂的bpi和其同源物
EP3003324A4 (en) 2013-05-28 2017-01-25 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
IT201700108102A1 (it) * 2017-09-27 2019-03-27 Univ Degli Studi Padova Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie
WO2019063320A1 (en) 2017-09-27 2019-04-04 Universita' Degli Studi Di Padova COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
EP3566717A1 (en) 2018-05-09 2019-11-13 Universität Regensburg Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262403A (en) * 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
EP1659132A1 (en) * 1987-08-11 2006-05-24 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
DE69128968T2 (de) * 1990-12-03 1998-10-08 Univ New York Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
US5357041A (en) * 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
WO1993013794A1 (en) * 1992-01-16 1993-07-22 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
ES2157981T3 (es) * 1993-03-12 2001-09-01 Xoma Technology Ltd Usos terapeuticos de productos proteicos bactericidas/aumentadores de la permeabilidad.
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof

Also Published As

Publication number Publication date
US5639727A (en) 1997-06-17
US5807818A (en) 1998-09-15
WO1994020128A1 (en) 1994-09-15
CA2157927A1 (en) 1994-09-15
HK1014497A1 (en) 1999-09-30
AU6360594A (en) 1994-09-26
CN1105574C (zh) 2003-04-16
EP0690720A1 (en) 1996-01-10
NZ263057A (en) 2000-12-22
DE69427582T2 (de) 2001-10-04
CA2157927C (en) 1999-03-30
EP1129718A3 (en) 2002-05-22
EP0690720B1 (en) 2001-06-27
PT690720E (pt) 2001-12-28
US20020090368A1 (en) 2002-07-11
EP1129718A2 (en) 2001-09-05
JP2005206606A (ja) 2005-08-04
JP2005187480A (ja) 2005-07-14
CN1124455A (zh) 1996-06-12
GR3036686T3 (en) 2001-12-31
DE69427582D1 (de) 2001-08-02
CN1478543A (zh) 2004-03-03
AU684503B2 (en) 1997-12-18
DK0690720T3 (da) 2001-08-27
ES2157981T3 (es) 2001-09-01
JPH08509703A (ja) 1996-10-15
MX9401807A (es) 1995-01-31

Similar Documents

Publication Publication Date Title
ATE202482T1 (de) Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
ATE431364T1 (de) Inhibitoren der menschlichen elastase von neutrophilen
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
ATE556713T1 (de) Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69224069D1 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
DK0690721T3 (da) Behandling af Mycobakterielle sygdomme ved indgivelse af baktericidt/permeabilitets-forøgende proteinprodukter
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DE69133485D1 (de) Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP0832100A4 (en) NOVEL METALLOPROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE
PT804465E (pt) Novos inibidores da elastase
DE60108076D1 (de) Protein c derivate
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
DK113789D0 (da) Thiosulfinsyrederivater, deres anvendelse til behandling af betaendelsessygdomme samt laegemiddel indeholdende disse stoffer
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
FI117320B (fi) Bradykiniiniantagonistien käyttö lääkeaineiden valmistamiseksi virussairauksien hoitamiseksi
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin
MX9204485A (es) Composicion farmaceutica para el tratamiento de enfermedades inflamatorias.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution
REN Ceased due to non-payment of the annual fee